With the completion of Catalina, EDF Renewable Energy is generating a combined 835 MW of clean energy for California. California solar photovoltaic project dedicated CPV says it has developed 400+ MW of renewable capacity on former coal mines 9.30.2013 Southern Power acquiring 118-MW Oklahoma wind project developed by Vestas’ NA unit Facebook Linkedin EDF Renewable Energy dedicated the 110 MW Catalina solar project in California. Linkedin No posts to display Twitter The project uses Solar Frontier and First Solar (Nasdaq: FSLR) photovoltaic (PV) modules. San Diego Gas & Electric signed a 25-year power purchase agreement for the output from the project. Facebook Renewable project management firm Bradley acquired by Bureau Veritas RenewablesNew ProjectsWind By chloecox – RELATED ARTICLESMORE FROM AUTHOR TAGSSDEG Previous articleFarley nuclear plant Unit 1 offline for planned maintenance outageNext articleSunPower to provide panels for Japanese solar power project chloecox Read more wind energy news Twitter
Dr. Donald Lloyd-Jones, a Northwestern University cardiologist and program chief for the heart conference, was more supportive. PHILADELPHIA (AP) – Novel drugs may offer fresh ways to reduce heart risks beyond the usual medicines to lower cholesterol and blood pressure. FILE – This May 26, 2009 file photo shows a printout from an electrocardiogram machine in Missouri. Doctors are reporting that novel drugs may offer fresh ways to reduce heart risks beyond the usual medicines to lower cholesterol and blood pressure. One new study found that heart attack survivors benefited from a medicine long used to treat gout. Gene-targeting medicines also showed promise in studies discussed Monday, Nov. 18, 2019, at an American Heart Association conference in Philadelphia. (AP Photo/Jeff Roberson) Colchicine is being tested in several other studies, and more evidence is needed before using it routinely to lower heart risks, Dr. L. Kristin Newby of Duke University wrote in a commentary published with the study in the New England Journal of Medicine. One new study found that heart attack survivors benefited from a medicine long used to treat gout. Several experimental drugs also showed early promise for interfering with heart-harmful genes without modifying the genes themselves – in one case, with treatment just twice a year. “There’s a lot of excitement” about the new gene-targeting medicines, especially because they seem to last so long, said Dr. Karol Watson, of the University of California, Los Angeles. Scientists have been exploring gene therapy – altering DNA – to attack the root cause of many diseases. The new drugs essentially accomplish the same thing without tampering with genes, said the University of Pennsylvania’s Dr. Daniel Rader, who has consulted for some makers of these drugs. The research was featured at an American Heart Association conference ending Monday in Philadelphia. Other research found new benefits from older drugs. AstraZeneca’s Farxiga, originally developed to treat diabetes, also lowered the risk of heart problems in heart failure patients who did not have diabetes. Among 2,605 of such patients treated for 18 months, about 9% of those on Farxiga had worsening heart failure or heart-related death versus nearly 13% of those not given the drug. That worked out to a 27% lower risk, without extra serious side effects. The drug lowered LDL by 56% without serious side effects. More testing will show whether it also lowers heart attacks and other problems, not just cholesterol. Inclisiran’s maker, The Medicines Company, plans to seek federal approval for it later this year. After about two years, colchicine users had a 23% lower risk of suffering a new heart attack, heart-related death, stroke, cardiac arrest or urgent need for an artery-opening procedure compared with a group given dummy pills. The benefit came mostly from preventing strokes and artery-opening procedures, and some heart doctors would rather have seen more difference in heart attacks and deaths. Each RNA interference drug was tested at various doses in 40 people. A single shot lowered triglycerides by 30% to 67%, and the benefit lasted for at least four months. The studies were just intended to show safety; Arrowhead Pharmaceuticals is developing both drugs. This May 26, 2009 file photo shows a printout from an electrocardiogram machine in Missouri. Doctors are reporting that novel drugs may offer fresh ways to reduce heart risks beyond the usual medicines to lower cholesterol and blood pressure. One new study found that heart attack survivors benefited from a medicine long used to treat gout. Gene-targeting medicines also showed promise in studies discussed Monday, Nov. 18, 2019, at an American Heart Association conference in Philadelphia. (AP Photo/Jeff Roberson) Surprising benefits also were seen in a Canadian study of the decades-old gout drug. The anti-inflammatory drug colchicine – sold as Colcrys, Mitigare and in generic form – was tested in 4,745 people who recently had a heart attack. “When you have a safe drug that’s easily available, it’s going to be hard to hold this one back,” he said. The medicines work by silencing or blocking messages that genes give to cells to make proteins that can do harm, such as allowing cholesterol to accumulate. The first few of these “RNA-interference” drugs recently were approved for other conditions, and research is also targeting heart disease. Farthest along is inclisiran, tested in 1,561 people with heart disease from clogged arteries who still had high LDL, the bad form of cholesterol, despite taking standard drugs. They were given a shot of inclisiran or a dummy drug when they joined the study, three months later and then every six months. Two other RNA interference drugs aim at a different target – triglycerides, another fat in the blood that’s elevated in one quarter of Americans. Treatments include very low-fat diets, weight loss, fish oil and drugs, but doctors say more and better therapies are needed.
The Vermont Republican State Committee met in Montpelier this past Saturday and unanimously elected Jack Lindley as the new VT GOP Chair. “It will take all of our energy and a lot of hard work, but this can and will be a great year for Vermont Republicans,” Lindley said. “We are going to engage our neighbors and talk about the issues, and we will lead the way towards greater growth, opportunity and prosperity for all Vermonters.” “Growing our economy and creating new and better jobs for Vermonters is our only hope to save our beautiful state and preserve our quality of life,” Lindley continued. “We need to push back against single-party rule in Montpelier, and we need to bring common sense back to the State House.” “Without a check on Governor Shumlin’s reckless agenda, we are steamrolling towards a very dangerous place,” Lindley said. “Vermont Democrats must be held responsible for the turmoil they have created in our health care system. They must be held responsible for the uncertainty they have created in our energy future. They must be held responsible for the angst and uncertainty they have created for Vermont’s small business owners.” Lindley is no stranger to Vermont politics, having served in several high-level political posts over the years. He was Vermont’s Republican National Committeeman from 1992 to 1996, and also served as Vermont Chair for three Presidential campaigns: Reagan-Bush (1980) and Bush-Quayle (1988 and 1992). He also served as VT GOP Chair from 1978 to 1981, and VT GOP Treasurer from 1975 to 1978.
The 48-year-old, who recently left his job at Chinese side Tianjin Tianhai, was heavily linked to Southampton, with reports from Portugal saying he was ‘ready to be the next Portuguese manager in the Premier League’.His arrival at St. Mary’s never happened, but Sousa is clearly up for a new challenge, as he made pretty clear in a five-page interview with newspaper Record on Sunday.Now besides his plans for the future, Sousa also talked about his past. And when asked about the time he’s had in the UK, where he’s worked at QPR, Swansea and Leicester City, the manager revealed a big regret for having left his position at the Welsh side.“I went through the Championship and I gained a lot of experience, beyond the passion that football transmits,” Paulo Sousa told Record.Embed from Getty Images“I started at Queens Park Rangers, went to Swansea and passed sporadically at Leicester – the owners changed, they hired Eriksson, they offered me the position of manager of football but I did not accept it.”By manager, Sousa means a football director, as he really used the word in English and didn’t mean it like the Portuguese word for coach.“It was a mistake to have left Swansea,” he said. “It’s one of those decisions that I regret, for being hasty. I want one day to return to the country and live that reality again in the Premier League.”by Taboolaby TaboolaSponsored LinksSponsored LinksPromoted LinksPromoted LinksTrending TodayForge of Empires – Free Online GameBuild a City, Trade With Your Neighbors, Play With Your FriendsForge of Empires – Free Online GameUndoRaid: Shadow Legends | Free DownloadEven Non-Gamers Are Obsessed With This RPG Game (It’s Worth Installing!)Raid: Shadow Legends | Free DownloadUndoDating.comWhere do attractive singles find each other in Tung Chung?Dating.comUndoPerfect-Dating.comReveal Tung Chung As The Best City to Date for Love & RomancePerfect-Dating.comUndoKeto减肥1個簡單的妙招一夜「融化」腹部贅肉（今晚試試）Keto减肥UndoCNBC InternationalHere’s How Big Businesses in Singapore Are Managing the Impact of COVID-19.CNBC InternationalUndo熱門話題小心會長過頭…網友推爆:「真的長得超誇張!」熱門話題UndoSingles50Hong Kong: A 40+ Dating Site That Actually Works!Singles50UndoCoworking Space | Search AdsThe cost of shared office in Hong Kong might surprise youCoworking Space | Search AdsUndo At the end of 2018, we covered a handful of stories about manager Paulo Sousa.